A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Trial Profile

A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions
  • Acronyms STEVIE
  • Sponsors Roche
  • Most Recent Events

    • 12 Dec 2017 Results (n=6) of retrospective data from advanced BCC patients enrolled in this clinical trial who discontinued vismodegib due to PD and were then retreated with the same drug, were published in the Targeted Oncology.
    • 23 Oct 2017 Results of primary analysis (n=1215, data cut-off :16 Mar 2015), published in the European Journal of Cancer.
    • 02 Aug 2017 Results of pooled retrospective analysis of this and other 3 studies published in the Journal of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top